Rabeximod - Cyxone

Drug Profile

Rabeximod - Cyxone

Alternative Names: ROB 803

Latest Information Update: 05 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OxyPharma
  • Developer Cyxone
  • Class Acetamides; Disease-modifying antirheumatics; Heterocyclic compounds with 4 or more rings; Small molecules
  • Mechanism of Action Cell differentiation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 01 Jun 2018 Cyxone completes acquisition of rabeximod from OxyPharma
  • 23 Nov 2017 Cyxone plans a phase IIb trial for Rheumatoid arthritis
  • 09 Feb 2016 Phase II development is ongoing in European Union, Georgia and Serbia and Montenegro
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top